You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a new approach to screening for language impairments
SBC: PANTHER TECHNOLOGY Topic: NIDCDDESCRIPTIONprovided by applicantThis Small Business Technology and TransferSTTRFast Track proposal focuses on the translation of innovative research protocols for diagnosing Specific Language ImpairmentSLIinto an innovativeeasy touse app based screener with high potential for private sector commercializationSLI is a form of language impairment with no known causewith a strong research baseBecause ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel highly effective influenza vaccine
SBC: FLUGEN INC Topic: NIAIDDESCRIPTION provided by applicant Seasonal influenza flu virus an NIAID category C priority pathogen causes widespread infection resulting in at least million cases of severe illness and deaths worldwide Young children and elderly or immunocompromised individuals are typically at greater risk of severe illness or death from influenza Newly emerging strains can result ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Peptide Antibiotic Nucleic Acids
SBC: NUBAD LLC Topic: NIAIDDESCRIPTION provided by applicant One of the challenges of research in infectious diseases is to find ways to use the increasing knowledge of the mechanisms underlying disease transformation and progression to develop novel therapeutic strategies for diseases such as increasing menace of bacterial infections Targeting specific RNA such as rRNA which are involved in proliferation and survival ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of VPL Vaccine for RSV
SBC: SIGMOVIR BIOSYSTEMS, INC. Topic: NIAIDProject Summary Human respiratory syncytial virus (RSV) is recognized as the single most important viral cause of acute respiratory disease in infants and young children worldwide. Elderly populations and immunocompromised individuals are also at significant risk for serious RSV disease. Despite this very substantial disease burden imposed by RSV worldwide, there are no vaccines available. Severa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Drug Delivery Method for Sudden Sensorineural Hearing Loss
SBC: WEINBERG MEDICAL PHYSICS, INC. Topic: NIDCDDESCRIPTION (provided by applicant): The ultimate goal of the proposed project is to evaluate and commercialize a combination of proprietary magnet assemblies and magnetic nanoparticles (initially developed by our University STTR partner), that has been shown in preliminary animal studies to improve delivery of medications to the inner ear. Initial animal studies using the system (which uses magne ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Effect of VBP15, a dissociative steroidal analogue, on intestinal epithelial repair processes in inflammatory bowel disease
SBC: REVERAGEN BIOPHARMA, INC. Topic: NIDDK? DESCRIPTION (provided by applicant): Glucocorticoids (e.g. prednisolone) are prescribed frequently to treat inflammatory bowel disease (IBD). Despite effectiveness, adverse side effects believed to be caused by GRE-mediated transcriptional propertieslimit long term use of glucocorticoids in IBD patients. Furthermore, these GRE-mediated transcriptional activities have been previously shown to ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat
SBC: TRAVERSE BIOSCIENCES, INC. Topic: NIADESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprie ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of VBP15 a dissociative steroidal analogue on pain and inflammation
SBC: REVERAGEN BIOPHARMA, INC. Topic: NIMHDDESCRIPTION (provided by applicant): The treatment of pain in Sickle Cell Disease (SCD) is challenging for both patients and providers and is associated with significant disparities in healt care delivery. While the role of ongoing inflammation during vasooclusive crisis and pain is recognized, effective therapeutic interventions are lacking. Glucocorticoids, with their anti-inflammatory propertie ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Fluorescence Image-Guided Near Infrared (NIR) Photodynamic Therapy (PDT) Agent
SBC: PHOTOLITEC LLC Topic: 102DESCRIPTION provided by applicant Photolitecandapos s patented technology is focused on developing improved agents for tumor imaging image guided surgery and or photodynamic therapy PDT The proposed STTR proposal includes fluorescence image guided PDT a andquot See and Treatandquot approach The fluorescence imaging compound with long wavelength absorption near nm should be extremel ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Image-guided planning system for skull correction in children with craniosynostos
SBC: KITWARE INC Topic: NICHDDESCRIPTION (provided by applicant): Craniosynostosis is the premature fusion of cranial sutures and occurs in approximately one in 2000 live births. It results in cranial malformation that can lead to elevated intra-cranial pressure, brain growth impairment, and developmental deficiency. The most common treatment option for craniosynostosis is surgery. Currently, surgical treatment planning of cr ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health